[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351444-105":59,"doc-detail-351444-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","redefining-standards-a-comprehensive-systematic-review-of-practice-changing-advances-in-gu-oncology-from-asco-and-esmo-2025","Redeﬁning standards - a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025","","The year 2025 marked a paradigm shift in genitourinary (GU) oncology, with major conference trial results rapidly translated into new evidence for clinical standards. This systematic review identifies and critically evaluates pivotal phase II and III randomized controlled trials from ASCO/ESMO 2025 or published in 2025, covering bladder, kidney, prostate, penile, and testicular cancers. Using PRISMA 2020 methods and risk-of-bias assessment, the review synthesizes overall and progression-free survival endpoints to support biomarker-driven care, immunotherapy integration, resistance mechanism insights, and treatment optimization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/redefining-standards-a-comprehensive-systematic-review-of-practice-changing-advances-in-gu-oncology-from-asco-and-esmo-2025/351444/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/redefining-standards-a-comprehensive-systematic-review-of-practice-changing-advances-in-gu-oncology-from-asco-and-esmo-2025/351444.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the document’s main purpose?","Question",{"text":112,"@type":113},"To identify, synthesize, and critically evaluate pivotal phase II and III randomized controlled trials from ASCO/ESMO 2025 or published in 2025 that change clinical practice across GU malignancies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the systematic review conducted?",{"text":117,"@type":113},"It followed PRISMA 2020 guidance and included exhaustive searches of conference proceedings and databases (PubMed/MEDLINE and Embase). Study selection, data extraction, and risk-of-bias assessment used the Cochrane RoB 2 tool.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of outcomes and treatments are emphasized in the results?",{"text":121,"@type":113},"The review focuses on overall survival and progression-free survival reported by phase II/III RCTs, highlighting advances such as immunotherapy integration, biomarker-driven strategies, novel resistance mechanisms, and treatment optimization across multiple GU cancer types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351444,1790834293,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Systematic Review PUBLISHED 01 April 2026  \nDOI 10.3389/fendo.2026.1780259  \nOPEN ACCESS  \nEDITED BY  \nSteven Kregel,  \nLoyola University Chicago, United States  \nREVIEWED BY  \nJure Murgic,  \nSisters of Charity Hospital, Croatia Xuezhou Zhang,  \nCapital Medical University, China  \n*CORRESPONDENCE  \nNabil Ismaili  \n [ismailinabil@yahoo.fr](ismailinabil@yahoo.fr)  \nRECEIVED 03 January 2026  \nREVISED 10 March 2026  \nACCEPTED 16 March 2026  \nPUBLISHED 01 April 2026  \nCITATION  \nIsmaili N (2026) Redeﬁning standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025 . Front. Endocrinol. 17:1780259 .  \ndoi: 10.3389/fendo.2026.1780259  \nCOPYRIGHT  \n© 2026 Ismaili. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nRedeﬁning standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025  \nNabil Ismaili 1,2*  \n1 Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Casablanca, Morocco, 2Oncopathology, Biology and Environment of Cancer Laboratory, Mohammed VI Center for Research and Innovation (CM6RI), Mohammed VI Foundation of Sciences and Health (FM6SS), Rabat, Morocco  \nBackground: The year 2025 has been a transformative moment in GU oncology, with paradigm-shifting clinical trial results presented at major conferences and rapidly published. These developments are recasting therapeutic standards across bladder, kidney, prostate, penile, and testicular cancers through novel mechanisms and reﬁned personalization.  \nObjectives: This systematic review aimed to identify, synthesize, and critically evaluate pivotal phase II and III randomized controlled trials presented at ASCO/ ESMO 2025 or published in 2025, focusing on innovative therapeutic strategies across GU malignancies.  \nMethods: Conducted per PRISMA 2020 guidelines, the review involved exhaustive searches of conference proceedings, PubMed/MEDLINE, and Embase (January-December 2025) . Included studies were phase II and III RCTsin GU oncology reporting overall or progression-free survival for novel therapies. Study selection, data extraction, and risk-of-bias assessment using the Cochrane RoB 2 tool were performed.  \nResults: Forty studies met inclusion criteria: bladder cancer (13), kidney cancer (9), prostate cancer (16), testicular cancer (1), and penile cancer (1) . Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enfortumab vedotin plus pembrolizumab (KEYNOTE-905/EV-303) set new standards, while HER2-targeted disitamab vedotin plus toripalimab (RC48-C016) improved metastatic survival. Upfront MRI staging (BladderPath) and kidney-sparing approaches (DISTINCT-I) advanced. (2) In kidney cancer, adjuvant durvalumab (RAMPART) and transcriptomic-guided therapy (OPTIC RCC) were established. LenCabo compared post-immunotherapy regimens, and FRUSICA-2 introduced a novel VEGF-TKI/IO combination. (3) In prostate cancer, enzalutamide plus leuprolide improved survival in high-risk biochemical recurrence (EMBARK) . Capivasertib plus abiraterone beneﬁted PTEN-deﬁcient metastatic hormone-sensitive disease (CAPItello-281) . The PSMAddition trial demonstrated that adding [177 Lu]Lu-PSMA-617 to standard therapy signiﬁcantly improved radiographic PFS in PSMA-positive mHSPC. Docetaxel scheduling was optimized (ARASAFE), and an AI model (STAMPEDE) identiﬁed patients for AR inhibitor beneﬁt. Novel agents like saruparib and pasritamig showed pro","cbCaivpbld3eNQmx","https://ap.wps.com/l/cbCaivpbld3eNQmx","pdf",4082139,25,"English","# Introduction\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Keywords","[{\"question\":\"What is the document’s main purpose?\",\"answer\":\"To identify, synthesize, and critically evaluate pivotal phase II and III randomized controlled trials from ASCO/ESMO 2025 or published in 2025 that change clinical practice across GU malignancies.\"},{\"question\":\"How was the systematic review conducted?\",\"answer\":\"It followed PRISMA 2020 guidance and included exhaustive searches of conference proceedings and databases (PubMed/MEDLINE and Embase). Study selection, data extraction, and risk-of-bias assessment used the Cochrane RoB 2 tool.\"},{\"question\":\"What kinds of outcomes and treatments are emphasized in the results?\",\"answer\":\"The review focuses on overall survival and progression-free survival reported by phase II/III RCTs, highlighting advances such as immunotherapy integration, biomarker-driven strategies, novel resistance mechanisms, and treatment optimization across multiple GU cancer types.\"}]","Redeﬁning standards - a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025 | PDF",1790094176,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/741ccd2e365f889b7646dc7234b66f39.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/403730520997f63cd8544da030002792.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ccb268e5f7d34dd7304f89a3a6003b6.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e139b6f9f73c3f51dd46f56993ebaefa.webp",980,1385]